10.6084/m9.figshare.9777104.v1 Teofila Seremet Teofila Seremet Yanina Jansen Yanina Jansen Simon Planken Simon Planken Hassan Njimi Hassan Njimi Mélanie Delaunoy Mélanie Delaunoy Hakim El Housni Hakim El Housni Gil Awada Gil Awada Julia Schwarze Julia Schwarze Marleen Keyaerts Marleen Keyaerts Hendrik Everaert Hendrik Everaert Danielle Lienard Danielle Lienard Véronique Marmol Véronique Marmol Pierre Heimann Pierre Heimann Bart Neyns Bart Neyns MOESM3 of Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy Springer Nature 2019 Translational research Liquid biopsy Circulating tumor DNA Monitoring Immunotherapy Metastatic melanoma BRAF/NRAS mutations monitoring 2019-09-06 04:32:19 Journal contribution https://springernature.figshare.com/articles/journal_contribution/MOESM3_of_Undetectable_circulating_tumor_DNA_ctDNA_levels_correlate_with_favorable_outcome_in_metastatic_melanoma_patients_treated_with_anti-PD1_therapy/9777104 Additional file 3: Table S1. Longitudinal monitoring of patients with progressive disease exclusively in the central nervous system. Table S2. Absolute values of longitudinal monitoring of patients with > 500 copies of mutated ctDNA/ml of plasma at baseline and/or at week 3.